Japan Approves Muscular Dystrophy Drug Price of 304 Million Yen

An advisory panel to Japan’s health minister decided Friday to allow public health insurance coverage for a gene therapy for muscular dystrophy beginning Feb. 20 and set the drug’s official price at about 304.97 million yen.  Elevidys, a one-time treatment for Duchenne muscular dystrophy in ambulatory patients aged 3-7, will become the country’s most expensive drug. Episode notes: ‘Japan Approves Muscular Dystrophy Drug Price of 300 M. Yen’: https://barrierfreejapan.com/2026/02/14/japan-approves-muscular-dystrophy-drug-price-of-300-m-yen/